HALB
Halberd Corp.

We have signed a revenue share agreement with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com) a business specializing in first responder medical care solutions for civilian, military, and government sectors. This aligns Athena GTX's expertise and vast connections with breakthrough IP owned by Halberd. Additionally, Halberd has also signed an agreement with CrodenHealth.com of Canada to produce, market, sell and distribute Halberd's patented low dose naltrexone (LDN+) product to non-military customers worldwide. Sales of LDN+ to the military will be coordinated exclusively by Athena GTX, consistent with their expertise and contacts. Halberd Corp is an R&D company developing treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurological and infectious diseases. Halberd's technology base consists of four issued patents and 22 pending patents. Halberd's mission is to create and develop safe and effective treatments for incurable and hard-to-treat diseases. For the near-term, we remain focused on our patented LDN+ drug and our patent-pending three-component nasal spray that mitigates the potential neurodegenerative cascade following head trauma. Animal tests at MSU with Halberd's nasal spray have achieved over 50% reduction in GlialFiblliary Acid Protein GFAP), the gold standard indicator of brain injury following head trauma. This product addresses an unmet need for use in the military, by first responders and contact sports teams.